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Abstract 
Nicotinamide adenine dinucleotide (NAD) belongs to the family of naturally occurring 
adenine dinucleotides, best known for their various intracellular roles. However, there is 
evidence that they can also be released from cells to act as novel extracellular signalling 
molecules. Relatively little is known about the extracellular actions of NAD, especially in 
the cardiovascular system. The present study investigated the actions of NAD in the rat 
thoracic aorta, porcine coronary artery and porcine mesenteric arteries, mounted in 
organ baths for isometric tension recording. In the rat thoracic aorta and porcine 
coronary artery, NAD caused endothelium-independent concentration-dependent 
vasorelaxations which were unaffected by palmitoylCoA, a P2Y1 receptor antagonist, but 
which were blocked by CGS15943, a non-selective adenosine receptor antagonist. In the 
porcine coronary artery, NAD-evoked relaxations were abolished by SCH58261, a 
selective A2A receptor antagonist. In the rat thoracic aorta, NAD evoked relaxations were 
attenuated by A2A receptor antagonism with SCH58261, but were unaffected by an A2B 
receptor antagonist, MRS1754. In contrast, in the porcine mesenteric artery, NAD 
evoked endothelium-independent contractions, which were unaffected by a P2 receptor 
antagonist, suramin, or by NF449, a P2X1 receptor antagonist, but were attenuated 
following P2X receptor desensitization with -meATP. In conclusion, the present results 
show that NAD can alter vascular tone through actions at purine receptors in three 
different arteries from two species; its molecular targets differ according to the type of 
blood vessel.   
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Introduction 
P1 and P2 receptors for purine and pyrimidine nucleosides and nucleotides are widely 
distributed in the cardiovascular system and are involved in diverse functions including 
regulation of vascular contractility, growth and inflammation [1-4]. P1 receptors mediate 
the actions of adenosine, and P2X and P2Y receptors mediate the actions of ATP, ADP, 
UTP, UDP and UDP-sugars. There are four adenosine receptors (A1, A2A, A2B and A3), 
seven P2X receptors (P2X1-7) and eight P2Y receptors (P2Y1,2,4,6,11,12,13,14). Nicotinamide 
adenine dinucleotide (NAD) and NAD phosphate (NADP), and their reduced forms NADH 
and NADPH, belong to the family of naturally occurring adenine dinucleotides. These 
molecules are best known for their various intracellular roles, including actions as 
coenzymes, involvement in post-translational modification of proteins, and as substrates 
for NADPH oxidases [5-7]. However, there is evidence that they can also be released 
from cells to act as novel extracellular signalling molecules. NAD (Figure 1) is released in 
a variety of smooth muscle tissues during stimulation of nerves, including those in 
canine mesenteric artery and urinary bladder of human, mouse and dog [8-11]. 
Moreover, transporters for NAD, including connexin 43, have been identified that 
mediate both intercellular and intracellular transport of NAD through membranes [12-
14], although this is controversial [15].  
Relatively little is known about the extracellular actions of NAD, especially in the 
cardiovascular system, but evidence obtained primarily in tissues outside the 
cardiovascular system indicates that NAD can act at cell surface purine receptors. Many 
of the actions of NAD can be explained through activation of adenosine receptors [16-
18]. NAD can be cleaved by ectoenzymes; nucleotide 
phosphodiesterase/pyrophosphatase I (E-NPP, CD203 family) allows the production of 
AMP, which can be hydrolyzed to adenosine by ecto-5′-nucleotidase (CD73). The ecto-
enzyme CD38 degrades NAD to yield ADP-ribose (ADPR), cyclic ADP-ribose (cADPR) and 
nicotinic acid adenine dinucleotide phosphate (NAADP), and its cell surface location 
suggests an important role in recycling of extracellular nucleotides [12, 19, 20]. NAD has 
also been identified as an agonist at P2Y1 receptors in HEK cells and mouse colonic 
muscle [10], P2Y11 receptors in human granulocytes [21], and P2X receptors in human 
monocytes (P2X1 and possibly also P2X4 and P2X7) [22]. Multiple purine receptors are 
co-expressed in blood vessels; vasocontraction is typically mediated by P2X1, P2Y2, P2Y4 
and P2Y6 receptors expressed on the smooth muscle, while vasorelaxation is mediated 
by endothelial P2Y1, P2Y2 and P2Y6 receptors, and by A2A and A2B receptors expressed on 
the endothelium and smooth muscle [3]. Hence the vascular actions of NAD cannot be 
predicted, but must be determined empirically. 
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In this study, responses to NAD in rat thoracic aorta, porcine mesenteric artery and 
porcine coronary artery were investigated using selective P1 and P2 receptor 
antagonists. We have recently shown that palmitoyl CoA (PaCoA) is an antagonist at 
P2Y1 receptors in the rat thoracic aorta and porcine mesenteric artery [23]. Hence, 
PaCoA was used to characterise the responses to NAD in different blood vessels, 
specifically to investigate the possible involvement of P2Y1 receptors. It has previously 
been shown that vasorelaxant P2Y1, P2Y2 and A2 receptors are expressed on the 
endothelium of the rat thoracic aorta [24, 25]. Porcine coronary arteries are reported to 
express vasorelaxant P2Y1, A1, A2A and A2B receptors [26-31]. Little is known about 
purine receptor expression in the porcine mesenteric artery, however, ADP mediated 
relaxations through P2Y1 receptors have been reported [23]. The present results show 
that NAD can alter vascular tone through actions at purine receptors in three different 
arteries from two species; its actions differ according to the type of blood vessel, since 
NAD evoked P2X-like receptor-mediated contraction in the porcine mesenteric artery, 
but A2A receptor-mediated relaxation in the porcine coronary artery and rat thoracic 
aorta. 
 
Materials and Methods 
Porcine mesenteries and hearts, obtained from a local abattoir (Woods abattoir, 
Clipstone, Mansfield, Nottinghamshire) and male Wistar rats (200-250 g), obtained from 
Charles River (England, UK), were used in this study. Porcine first order mesenteric 
arteries and coronary arteries were dissected out and stored overnight in Krebs-
Henseleit solution (at 4o C) for use the following day. Rat thoracic aorta were dissected 
out, and rings (3-4 mm in length) from these and the porcine mesenteric and coronary 
arteries were mounted for isometric recording in Krebs-Henseleit solution, oxygenated 
(95% O2, 5% CO2) and incubated at 37o C as described previously [23]. Rat thoracic 
aortae were initially tensioned to 1 g and allowed to equilibrate for 30 min after which a 
further 1 g of tension was applied and the rings left to equilibrate for a further 30 min. 
Porcine coronary and mesenteric arteries were tensioned to 10 g and allowed to 
equilibrate for 1 h. After equilibration, arteries were contracted twice to KCl (60 mM), 
with washout after each addition, to act as an internal standard. Subsequently, arteries 
were preconstricted using methoxamine for the rat thoracic aorta and U46619, a 
thromboxane A2 mimetic, for porcine mesenteric and coronary arteries. Once a stable 
pre-contracted tone had been achieved, stepwise cumulative addition of NAD (0.1 µM- 1 
mM) to the preparations was carried out, in the absence and presence of selective 
antagonists. The antagonists/blockers used were: PaCoA (10 µM) (a putative 
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endogenous antagonist of P2Y1 receptors), CGS15943 (10 µM; an adenosine receptor 
antagonist), SCH58261 (100 nM; a selective A2A receptor antagonist), suramin (100 µM; 
a P2 receptor antagonist), αβ-meATP (10 µM; a P2X receptor agonist and desensitizing 
agent), and NF449 (10 µM; a P2X1 receptor antagonist). These compounds were added 
10 min before methoxamine or U46619 addition, and so were in contact with the tissue 
for at least 30 min before addition of NAD. In some preparations, the endothelium was 
removed by gentle rubbing with the success of the treatment evaluated by testing 
responses to acetylcholine in the rat aorta and substance P in the porcine arteries as 
described previously [23]. U46619 and substance P were used in the pig arteries, 
because they respond poorly to methoxamine and acetylcholine (used in the rat aorta). 
Materials 
Krebs-Henseleit buffer was composed of the following (mM); NaCl 118, KCl 4.8, 
CaCl2.H2O 1.3, NaHCO3 25.0, KH2PO4 1.2, MgSO4.7H2O 1.2 and glucose 11.1. The 
supplier for chemicals in this work was Sigma Chemical Company, except for SCH58261 
which was a gift from Schering Plough, Milan, Italy, and NF449 which was from Tocris 
Bioscience. All drugs were dissolved in water except for CGS15943 and SCH58261, 
which were dissolved in DMSO.  
Statistical analysis 
Responses are expressed as a percentage of the methoxamine- or U46619-induced tone. 
Data are expressed as mean ± SEM. Two way ANOVA with a Bonferroni post-hoc test 
was used for statistical comparisons. P < 0.05 was taken as statistically significant.  
 
Results 
KCl (60 mM) produced sustained contractions in the segments of rat thoracic aorta, 
porcine mesenteric artery and porcine coronary artery with mean responses of 0.91  
0.08 g (n=35), 9.21  0.43 g (n=20), and 9.96  0.20 g (n=32), respectively.  
Effect of NAD in precontracted rat thoracic aorta, porcine mesenteric artery and 
porcine coronary artery 
In the rat thoracic aorta, NAD evoked concentration-dependent relaxations (Figure 2a, 
4). The response to NAD did not reach a maximum response at concentrations up to 1 
mM, but almost fully reversed the methoxamine-induced precontraction allowing the 
calculation of an approximate pEC50 value of 4.24 ± 0.19 (n = 9). Endothelium removal 
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had no significant effect on the NAD induced relaxations (two way ANOVA, P> 0.05) 
(Figure 2a). 
In porcine mesenteric artery segments precontracted with U46619, NAD evoked 
concentration dependent contractions with a maximal contraction at 300 µM (Figure 2b, 
6). The highest concentration of NAD used (1 mM) caused a reduced contraction of the 
porcine mesenteric artery. Non-linear analysis allowed computation of an Rmax value of 
46 ± 8 %, pEC50 value of 4.54 ± 0.22 and a Hill slope of 1.05 ± 0.12 (n=12). 
Endothelium removal had no significant effect on the NAD-induced responses (Figure 
2b). 
In porcine coronary artery segments precontracted with U46619, NAD evoked 
concentration dependent relaxations (Figure 2c). The response to NAD did not reach a 
maximum response, so Rmax, pEC50 or Hill slope could not be calculated. Endothelium 
removal produced no significant effect on the NAD induced relaxations (Figure 2c). 
In porcine mesenteric artery and porcine coronary artery segments, endothelium 
removal was assessed using substance P (10 nM), while acetylcholine (100 nM) was 
used to assess endothelium removal in the rat thoracic aorta. Any relaxation in response 
to substance P/acetylcholine of less than 10% of the U46619/methoxamine contraction 
was considered an indication of successful removal of the endothelium. In endothelium-
denuded porcine mesenteric artery and porcine coronary artery, there was an absence of 
the transient relaxation in response to substance P (6 ± 1 % (n = 6) and 2 ± 1 % (n = 
5), respectively) that was seen in control porcine mesenteric and porcine coronary artery 
segments (60 ± 1 % (n = 11) and 70 ± 1 % (n = 6), respectively). In rat thoracic aorta 
there was only a very slight relaxation (2 ± 0.4 %, n = 7) in response to acetylcholine in 
endothelium-denuded vessels compared to the profound relaxation evoked in controls 
(65 ± 0.4 %, n = 10). 
Effect of P1 and P2 receptor antagonists on responses to NAD in the rat 
thoracic aorta 
Since NAD is able to act as an agonist at the P2Y1 receptor, PaCoA was used to 
investigate whether NAD activates P2Y1 receptors in the rat thoracic aorta. PaCoA had no 
significant effect on the vasorelaxant response to NAD (P> 0.05, two way ANOVA) 
(Figure 3a).  
Since NAD is able to act as an adenosine receptor agonist, CGS15943 (1 µM; a non-
selective adenosine receptor antagonist) was also investigated, which significantly 
inhibited the NAD evoked relaxations (Figure 3b). SCH58261 (100 nM; an A2A receptor-
selective antagonist) was used, which also significantly decreased the NAD evoked 
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relaxations with a calculated pKB value of 7.25 ± 0.24 (Figure 3c). A representative trace 
showing the inhibitory effect of SCH58261 on responses to NAD is shown in Figure 4. 
The possible involvement of A2B receptors was also investigated using MRS1754 (1 µM; a 
selective A2B receptor antagonist), which had no significant effect on NAD-evoked 
relaxations (Figure 3d). 
These experiments in rat thoracic aorta were carried out in methoxamine-precontracted 
tissues. In the absence of antagonists, methoxamine caused a sustained contraction to 
68  6% (n=13) of the KCl response. The bath concentration of methoxamine required 
to produce this level of contraction was 1.4  0.2 µM (n= 13). In the presence of PaCoA, 
SCH58261 and CGS15943, the level of tone was 70  6% (n= 6), 74  5% (n = 15) and 
59  4% (n= 5) of the KCl contraction, respectively. There was no significant difference 
between the percentage contractions obtained to methoxamine in the presence of the 
antagonists and the control (P> 0.05, one way ANOVA). In the presence of PaCoA, 
SCH58261 and CGS15943, the mean bath concentration of methoxamine required to 
precontract the arteries was also unchanged when compared to the control (one way 
ANOVA, P>0.05). 
Effect of P1 and P2 receptor antagonists on responses to NAD in porcine 
mesenteric artery 
To test for any involvement of P2 receptors in the NAD-mediated contractile response of 
the porcine mesenteric artery, suramin (100 µM; a P2 receptor antagonist) was 
employed; it had no significant effect except at the highest NAD concentration where 
suramin prevented the reduction in NAD-evoked contraction (Figure 5a). In contrast, αβ-
meATP (10 µM; a P2X receptor desensitizing agonist) caused a significant inhibition of 
the NAD evoked responses (Figure 5b, 6). αβ-meATP markedly inhibited or abolished the 
NAD responses of the mesenteric arterial preparations (thus an EC50 value could not be 
calculated). A mean contraction of 45  10 % and 17  7 % (n= 7, n=8, respectively) at 
300 µM NAD was found in the absence and presence of αβ–meATP, respectively. NF449 
(10 µM; P2X1 receptor antagonist) had no significant effect on the contractile response 
to NAD; mean contraction was 36 ± 5 % and 37 ± 7 % (n = 9) in the absence and 
presence of NF449, respectively.   
Since multiple contractile and relaxant purine receptors are typically expressed on blood 
vessels, we hypothesised that the contractile actions of NAD could be augmented 
following antagonism of NAD-mediated vasorelaxation. Since NAD can act as an agonist 
at the P2Y1 receptor, the effect of PaCoA was investigated. PaCoA at 10 μM had no 
significant effect on the response to NAD (P>0.05, two way ANOVA) (Figure 7a). NAD 
can also act at P1 receptors, hence the effects of CGS15943 (10 µM; a non-selective 
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adenosine receptor antagonist) and SCH58261 (100 nM; a selective A2A receptor 
antagonist) were investigated; neither had any significant effect on the response to NAD 
(Figure 7b, c). Adenosine produced concentration-dependent relaxation of the porcine 
mesenteric artery with an Rmax of 87 ± 4%, and a pEC50 of 3.87 ± 0.07 (n = 6). 
The above experiments in porcine mesenteric artery were carried out in vessels 
precontracted with U46619. In the absence of antagonists, U46619 caused a sustained 
contraction to 75  4 % (n= 7) of the KCl response. The concentration of U46619 
required to produce this level of contraction was 131  18 nM (n= 7). In the presence of 
PaCoA, SCH58261, suramin and αβ-meATP, U46619 elicited 65  9 % (n= 7), 63  5 % 
(n= 4), 50  10% (n= 4) and 58  3% (n= 8) of the KCl contraction, respectively, which 
was not significantly different from the control (P>0.05, one way ANOVA). The 
concentration of U46619 required to produce these contractions was unchanged (P> 
0.05, one way ANOVA). In the presence of CGS15943, a higher concentration of U46619 
(763 ± 259 nM, n = 6) was required to precontract the preparations compared to that 
used in the absence of CGS15943 (531 ± 216 nM, n = 7). There was no significant 
difference in the level of tone elicited in the absence and presence of CGS15943 at 55  
6% (n = 7) and 49  10% (n = 6) of the KCl contraction, respectively. There was no 
significant difference in the level of tone elicited in the absence and presence of NF449, 
at 61 ± 5 % and 62 ± 6 % (n = 9), respectively.  
Effect of P1 and P2 receptor antagonists on responses to NAD in porcine 
coronary artery 
Since NAD can act as an agonist at the P2Y1 receptor, PaCoA (10 µM) was used to 
investigate whether NAD activates P2Y1 receptors in the porcine coronary artery. PaCoA 
had no significant effect on the vasorelaxant response to NAD (P>0.05, two way ANOVA) 
(Figure 8a). To characterise the NAD-evoked relaxations, we used CGS15943 (10 µM; 
adenosine receptor antagonist) which, with the exception of the response to the highest 
concentration of NAD (1 mM), abolished the NAD evoked relaxations (Figure 8b). In the 
presence of CGS15943, contractions were observed at 10-100 µM of NAD; these were 
unaffected by the P2X1 receptor antagonist NF449 (10 µM) (data not shown). SCH58261 
(100 nM; selective A2A receptor antagonist) abolished the NAD-evoked relaxations 
(Figure 8c, 9).  
The above experiments in porcine coronary artery were carried out in U46619-
precontracted tissues. In the absence of antagonists U46619 caused a sustained 
contraction to 60  6% (n=9) of the KCl response. The concentration of U46619 required 
to produce this level of contraction was 145  62 nM (n= 9). In the presence of PaCoA 
and SCH58261 U46619 elicited 65  5% (n=5) and 76  2% (n=6) of the KCl 
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contraction, respectively, which was not significantly different from the control (one way 
ANOVA, P>0.05). The mean bath concentration of U46619 required was unchanged (one 
way, ANOVA P>0.05).  
In the presence of CGS15943, a higher concentration of U46619 was required to 
precontract the PCA preparations; for these experiments, 175 ± 79 nM (n = 7) of 
U46619 was needed to achieve 57  7% (n = 7) of the KCl contraction in controls, while 
773 ± 204 nM (n = 6) of U46619 was needed to elicit 24  4% (n = 6) of the KCl 
contraction in the presence of CGS15943. Both the level of contraction to U46619 and 
the concentration of U46619 required to achieve that level were significantly different 
from the control (P< 0.05, one way ANOVA). 
 
Discussion 
The effects of NAD on the rat thoracic aorta, porcine mesenteric artery and porcine 
coronary artery were examined. NAD evoked vasorelaxations through actions at smooth 
muscle A2A adenosine receptors in the rat thoracic aorta and porcine coronary artery. In 
the porcine mesenteric artery, however, NAD caused vasoconstriction, which was 
mediated through P2X receptors. NAD, therefore, evokes different effects (relaxation or 
contraction) in different blood vessels acting via different receptors. 
In the rat thoracic aorta and porcine coronary artery, NAD caused endothelium-
independent vasorelaxations. The effect of PaCoA, a P2Y1 receptor antagonist [23, 32, 
33], on the NAD-evoked relaxations was investigated, since NAD can act as an agonist at 
P2Y1 receptors [10]. PaCoA had no significant effect on the NAD-evoked relaxations, 
which, together with the fact that these relaxations were endothelium independent (P2Y1 
receptors are expressed on the endothelium in the rat aorta, see Introduction), indicates 
that P2Y1 receptors do not mediate these vasorelaxations. NAD has previously been 
shown to act as an agonist at adenosine receptors, without specification of which 
subtype was involved [16-18]. Hence, P1 receptor antagonists were initially used to 
characterise the NAD-mediated relaxations, followed by the use of more selective 
adenosine receptor antagonists. CGS15943, a non-selective adenosine receptor 
antagonist, significantly reduced the NAD evoked relaxations indicating the involvement 
of adenosine receptors. SCH58261, a selective A2A receptor antagonist, also significantly 
reduced the NAD-evoked relaxations, which indicates that NAD-evoked relaxations in the 
rat thoracic aorta and porcine coronary artery are mediated through A2A adenosine 
receptors. In contrast to the porcine coronary artery, relaxations to NAD in the rat 
thoracic aorta were not abolished in the presence of SCH58261, which may indicate the 
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involvement of other adenosine receptors in addition to A2A receptors. An A2B adenosine 
receptor antagonist, MRS1754, had no significant effect on the NAD-evoked relaxations 
in the rat thoracic aorta, which appears to exclude an involvement of A2B adenosine 
receptors. In the rat thoracic aorta, NAD had an approximate pEC50 value of 4.24. This is 
similar to the pD2 value reported by Burnstock and Hoyle [16] for NAD-evoked 
relaxations in the guinea-pig taenia coli at P1 receptors (4.18), but is somewhat different 
from the pEC50 value identified by Mutafova-Yambolieva et al. [10] for NAD-evoked 
calcium responses in HEK cells at P2Y1 receptors (6.1). The potency differences 
presumably reflect simple differences in the receptors being activated. In rat thoracic 
and porcine coronary arteries NAD appears to act at adenosine receptors, specifically as 
an A2A receptor-selective agonist. 
In the rat thoracic aorta and porcine coronary artery, NAD evoked relaxations were 
mediated mainly via actions at smooth muscle A2A receptors. This may be by NAD 
activating A2A receptors directly, by causing a release of adenosine, or by being broken 
down into adenosine. NAD is suggested to be broken down to adenosine to exert its 
effects in the guinea-pig taenia coli [16]. However, NAD was reported to evoke the 
release of adenosine in rat vas deferens, guinea-pig taenia caecia and bladder [34]. We 
have previously shown in the porcine coronary artery that ADP may mediate relaxation 
through release of adenosine with subsequent actions on smooth muscle A2A receptors 
[31]. Hydrolysis of NAD could be investigated using selective inhibitors of CD38 (an 
NAD-glycohydrolase), such as β-araF-NAD [35], but unfortunately these are not 
commercially available.  
 
In the porcine mesenteric arteries, NAD caused an endothelium-independent 
vasoconstriction up to a concentration of 300 µM. The P2 receptor antagonist suramin 
had no significant effect on these contractile responses to NAD. αβ-meATP (a P2X 
receptor desensitizing agonist) caused a significant attenuation of the NAD-evoked 
contractions, suggesting activation of a suramin-insensitive P2X receptor. αβ-meATP has 
been shown to produce transient contractile responses in porcine mesenteric arteries, 
indicating that rapidly desensitizing P2X1 receptors are expressed in these arteries [36]. 
The responses to NAD in the porcine mesenteric arteries, however, were not completely 
abolished in the presence of αβ-meATP. It was reported previously that rat large 
mesenteric arteries have a 25-100-fold lower sensitivity to αβ-meATP as an agonist than 
smaller arteries, and are insensitive to suramin, which is not characteristic of P2X1 
receptors [37]. Moreover, NF449, a P2X1 receptor antagonist, had no significant effect 
on the contractile response to NAD. The fact that cumulative contractile response curves 
could be generated in the porcine mesenteric arteries indicated a relative lack of 
desensitization, which is also inconsistent with NAD actions at rapidly desensitizing P2X1 
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receptors. Since relatively large mesenteric arteries were also used in this study this 
could suggest that, as in the rat large mesenteric arteries, non-P2X1 receptors or 
heteromeric P2X receptors are involved, but the response could also involve P2Y 
receptors. In our porcine mesenteric artery segments, the pEC50 for NAD was 4.54. NAD 
has been identified as an agonist at P2X1, P2X4 and P2X7 receptors in human 
monocytes [22], and NADPH mediated contractions of rat aorta were mediated via P2X1 
receptors [38], but there are no reported potency estimates for NAD acting through P2X 
receptors in the literature.  
 
In a number of cell types extracellular NAD signals through conversion into cADPR, which 
in turns mobilises intracellular Ca2+ [12, 14, 39-41]. In human monocytes, exposure to 
NAD resulted in activation of P2X receptors and a rapid increase in [Ca2+]i caused by an 
influx of extracellular Ca2+ independent of intracellular Ca2+; the possibility of NAD acting 
through a degradation product was ruled out using selective inhibitors of CD38 and a 
stable NAD analogue [22, 42]. Pfister et al. analyzed the NAD degradation products in 
human monocytes, and found that NAD was mainly degraded to ADP-ribose, 
nicotinamide, and minor amounts of AMP, ADP, and cADPR, but adenosine was not 
detected [43]. These metabolites can all have extracellular actions mediated through 
different purine receptors. Neither ADP nor AMP are agonists at P2X receptors, but ADP-
ribose (but not nicotinamide), mimicked the effect of NAD at P2X receptors in human 
monocytes [42]. Thus, ADP-ribose, formed from metabolism of NAD, is potentially 
involved in the vasocontractile responses that we observed in the porcine mesenteric 
arteries.  
 
Since multiple contractile and relaxant purine receptors are expressed on blood vessels, 
we hypothesised that the contractile actions of NAD in the porcine mesenteric artery 
could be augmented following antagonism of opposing NAD-mediated vasorelaxation. 
However, neither CGS15943 nor SCH58261 had a significant effect on the contractile 
response to NAD in the porcine mesenteric artery, indicating a lack of involvement of 
adenosine receptors. The reduction in NAD-evoked contraction which occurred at the 
highest concentration of NAD (1 mM) was blocked by suramin suggesting that it may be 
mediated through P2 receptors. PaCoA did not mimic the effect of suramin, suggesting 
that NAD fails to act through P2Y1 receptors in this tissue, either directly, or for example 
through metabolism to ADP-ribose which has been shown to be a ligand for the P2Y1 
receptor [44]. Thus, further investigation is needed as to whether a metabolite of the 
NAD, for example, ADP or ATP, may be responsible for this relaxation, or whether NAD 
itself activates suramin-sensitive P2Y receptors.  
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The actions of NAD in the porcine mesenteric arteries are clearly different to those in the 
rat aorta and porcine coronary artery, and also to mesenteric arteries in other species. 
We showed that adenosine produces concentration-dependent vasorelaxation of the 
porcine mesenteric artery, which is important because this shows that the pronounced 
differences in vasomotor responses of NAD between the different blood vessels are not 
simply due to a differential expression of adenosine receptors. In the rat mesenteric 
arterial bed, NAD did not elicit vasocontraction, but caused vasorelaxation, and inhibited 
sympathetic and sensory neurotransmission, effects which were antagonised by 8-para-
sulphophenyltheophyline and potentiated in the presence of an adenosine deaminase 
inhibitor, indicating an involvement of adenosine and adenosine receptors [18]. These 
effects of NAD mimic the actions of adenosine in the rat mesenteric arterial bed 
indicating a likely involvement of postjunctional vasorelaxant A2B receptors and 
prejunctional A1 receptors [45, 46]. NAD also inhibited neuronal noradrenaline release in 
the dog mesenteric artery [8], an effect likely mediated via A1 adenosine receptors given 
their widespread occurrence prejunctionally on sympathetic perivascular nerves [3]. 
Thus, NAD actions in the porcine mesenteric artery appear to deviate from those in other 
arteries for reasons which are currently unclear. It would be interesting to carry out a 
comparative investigation of ectoenzyme expression of the porcine mesenteric and other 
arteries. 
The most robust evidence for a physiological role for extracellular NAD is as a 
neurotransmitter in nerves of the gastrointestinal tract and bladder [11]. Whether this is 
relevant for the sparsely innervated rat thoracic aorta and porcine coronary artery 
remains to be determined, but it could be relevant for sympathetic neurotransmission in 
the porcine mesenteric artery; it would be interesting to determine whether there is a 
role for NAD as a neurotransmitter in porcine mesenteric arteries, as shown in canine 
mesenteric arteries [8]. Extracellular signalling of NAD could also be important in 
pathophysiological conditions leading to cell lysis during tissue injury and inflammation, 
conditions which are known to release other purine nucleotides [3]. 
In conclusion, there are clear differences in the actions of NAD in the porcine mesenteric 
artery compared to the rat thoracic aorta and porcine coronary artery; in both rat 
thoracic aorta and porcine coronary artery, NAD mediates relaxation through P1 
receptors, while in porcine mesenteric artery NAD causes contraction which appears to 
involve P2 receptors whose identity remains to be defined. The suggestion that NAD may 
be broken down to adenosine to act through P1 receptors may indicate higher levels of 
ectonucleotidases in rat thoracic aorta and porcine coronary artery than in the porcine 
mesenteric artery. 
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Figure legends 
Figure 1 Chemical structure of nicotinamide adenine dinucleotide. 
Figure 2.The effect of nicotinamide adenine dinucleotide (NAD) in segments from: A) rat 
thoracic aorta (RTA), B) porcine mesenteric artery (PMA), C) porcine coronary artery (PCA). 
Arteries were precontracted with methoxamine (A) and U46619 (B,C). Responses were 
evaluated in endothelium intact vessels (Control) and in those in which the endothelium had 
been removed (Denuded) in each of the RTA, PMA and PCA (n= 7-10, n= 6-11, n= 5-6, 
respectively). Results are mean  SEM. 
Figure 3. Relaxatory responses in the rat thoracic aorta to nicotinamide adenine 
dinucleotide (NAD) in the presence of A) PaCoA, B) CGS15943, C) SCH58261 and D) 
MRS1754. Vessels were precontracted with methoxamine. Results are shown as mean  
SEM (n=5-6, n=4-5, n=12-15 and n=4-8, respectively). * P < 0.5, ** P < 0.01, *** P < 
0.001. 
Figure 4. A representative trace for the relaxatory responses to cumulative addition of 
increasing concentrations of nicotinamide adenine dinucleotide (NAD) in the rat thoracic 
aorta in the absence (Control, upper trace) and the presence of SCH58261 (SCH58261, 
lower trace). Vessels were precontracted with methoxamine. 
Figure 5. The contractile response of porcine mesenteric artery to nicotinamide adenine 
dinucleotide (NAD) in the absence and presence of A) suramin, B) α,β-meATP. The arteries 
had been precontracted with U46619. Results are shown as mean  SEM (n=4, n= 7-8, 
respectively). ** P < 0.01, *** P < 0.001. 
Figure 6. A representative trace for the contractile response to nicotinamide adenine 
dinucleotide (NAD) of porcine mesenteric artery in the absence (Control, upper trace) and 
presence of αβ-meATP (αβ-meATP, lower trace). The arteries had been precontracted with 
U46619.  
Figure 7. The porcine mesenteric artery contractile response to nicotinamide adenine 
dinucleotide (NAD) in the presence of A) PaCoA, B) CGS15943, C) SCH58261 (n=7, n=8, 
n=4, respectively). The arteries had been precontracted with U46619. Results are shown as 
mean  SEM. 
Figure 8. The porcine coronary artery relaxation to nicotinamide adenine dinucleotide 
(NAD) in the presence of A) PaCoA, B) CGS15943, C) SCH58261. Preparations were 
15 
 
precontracted with U46619. Results are shown as mean  SEM (n=5, n=6, n=6 
respectively). * P < 0.5, ** P < 0.01, *** P < 0.001. 
Figure 9. A representative trace for the porcine coronary artery relaxation to nicotinamide 
adenine dinucleotide (NAD) in the absence (Control, upper trace) and presence of 
SCH58261 (SCH58261, lower trace). Vessels were precontracted with U46619.  
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Figure 1 Chemical structure of nicotinamide adenine dinucleotide. 
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